Inhibiting WEE1 Augments the Antitumor Efficacy of Cisplatin in Urothelial Carcinoma by Enhancing the DNA Damage Process

Urothelial carcinoma (UC) is characterized by a high incidence of TP53 mutation, and overcoming resistance to cisplatin-based chemotherapy in UC is a major concern. Wee1 is a G2/M phase regulator that controls the DNA damage response to chemotherapy in TP53-mutant cancers. The combination of Wee1 bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Yu-Li, Xiao, Ling-Yi, Huang, Shih-Yu, Wu, Chia-Che, Chang, Li-Chung, Chen, Yi-Hua, Luo, Hao-Lun, Huang, Chun-Chieh, Liu, Ting-Ting, Peng, Jei-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252844/
https://www.ncbi.nlm.nih.gov/pubmed/37296592
http://dx.doi.org/10.3390/cells12111471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252844/
https://www.ncbi.nlm.nih.gov/pubmed/37296592
http://dx.doi.org/10.3390/cells12111471

Ejemplares similares